Qureator, Inc
- Biotech or pharma, therapeutic R&D
AI can design better molecules—but without human-relevant biological context, it can’t unlock real therapeutic breakthroughs. Despite hundreds of AI-discovered drug candidates, none have received regulatory approval. Why? Because the complexity of human disease and the lack of clearly defined biological targets make it impossible to treat effectively using algorithms alone.
Qureator is the missing piece.
We provide the biological engine AI needs to succeed.
- Human Biology First: We build next-generation human disease models using proprietary organ-on-a-chip (OoC) technology that replicates complex disease phenotypes and patient-specific responses.
- AI + Real-World Biology: Our platform bridges the gap between digital predictions and clinical success—unlocking new targets, reducing trial failures, and accelerating drug timelines.
- Clinically Validated, FDA-Aligned: We partner with pharma, biotech, FDA, and NIH to deliver regulatory-ready models rooted in human physiology.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}